

Euichaul Oh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6470832/publications.pdf>

Version: 2024-02-01

37
papers

600
citations

567281

15
h-index

677142

22
g-index

37
all docs

37
docs citations

37
times ranked

990
citing authors

#	ARTICLE	IF	CITATIONS
1	New method and characterization of self-assembled gelatin-oleic nanoparticles using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 89, 365-373.	4.3	63
2	Kinematic evaluation of movement smoothness in golf: relationship between the normalized jerk cost of body joints and the clubhead. <i>BioMedical Engineering OnLine</i> , 2014, 13, 20.	2.7	39
3	Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles. <i>Biomedicine and Pharmacotherapy</i> , 2016, 80, 162-172.	5.6	28
4	Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice. <i>PLoS ONE</i> , 2016, 11, e0153965.	2.5	28
5	Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1133-1141.	2.0	27
6	Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats. <i>Xenobiotica</i> , 2014, 44, 1099-1107.	1.1	26
7	Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition. <i>Food and Chemical Toxicology</i> , 2014, 68, 117-127.	3.6	25
8	In vitro stereoselective inhibition of ginsenosides toward UDP-glucuronosyltransferase (UGT) isoforms. <i>Toxicology Letters</i> , 2016, 259, 1-10.	0.8	24
9	Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1533-1543.	2.0	23
10	Preformulation Studies on the S-Isomer of Oxybutynin Hydrochloride, an Improved Chemical Entity (ICE ₁ , Φ). <i>Drug Development and Industrial Pharmacy</i> , 2001, 27, 321-329.	2.0	21
11	Cell-penetrating peptide-based non-invasive topical delivery systems. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 77-87.	5.3	21
12	Rationale and strategies for formulation development of oral fixed dose combination drug products. <i>Journal of Pharmaceutical Investigation</i> , 2016, 46, 615-631.	5.3	18
13	pH-independent controlled release tablets containing nanonizing valsartan solid dispersions for less variable bioavailability in humans. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 46, 365-377.	3.0	18
14	Improving the dissolution rate of a poorly water-soluble drug via adsorption onto pharmaceutical diluents. <i>Journal of Drug Delivery Science and Technology</i> , 2016, 35, 146-154.	3.0	17
15	Formulation and evaluation of an alternative triglyceride-free propofol microemulsion. <i>Archives of Pharmacal Research</i> , 2010, 33, 1375-1387.	6.3	15
16	In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions. <i>Toxicology Letters</i> , 2015, 232, 458-465.	0.8	15
17	Employing an optimized spray-drying process to produce ezetimibe tablets with an improved dissolution profile. <i>Journal of Pharmaceutical Investigation</i> , 2016, 46, 583-592.	5.3	15
18	Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin. <i>Archives of Pharmacal Research</i> , 2017, 40, 391-402.	6.3	15

#	ARTICLE	IF	CITATIONS
19	Reprecipitation of poorly water-soluble cilostazol crystals using adsorbing carriers for enhanced dissolution and physicochemical modification. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 43, 477-486.	3.0	15
20	Investigation of Crystallization and Salt Formation of Poorly Water-Soluble Telmisartan for Enhanced Solubility. <i>Pharmaceutics</i> , 2019, 11, 102.	4.5	15
21	Prediction of the Hiestand Bonding Indices of Binary Powder Mixtures from Single-Component Bonding Indices. <i>Pharmaceutical Development and Technology</i> , 1999, 4, 65-70.	2.4	14
22	Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 1117-1124.	5.6	12
23	Metabolic Drug-Drug Interaction Potential of Macrolactin A and 7-O-Succinyl Macrolactin A Assessed by Evaluating Cytochrome P450 Inhibition and Induction and UDP-Glucuronosyltransferase Inhibition In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5036-5046.	3.2	12
24	Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3961.	4.3	12
25	Induction of vascular leak syndrome by tumor necrosis factor-alpha alone. <i>Biomedicine and Pharmacotherapy</i> , 2015, 70, 213-216.	5.6	12
26	Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. <i>International Journal of Pharmaceutics</i> , 2017, 523, 343-356.	5.2	12
27	Consecutive One-Pot versus Domino Multicomponent Approaches to 3-(Diarylmethylene)oxindoles. <i>Molecules</i> , 2017, 22, 503.	3.8	12
28	Effect of biomimetic shear stress on intracellular uptake and cell-killing efficiency of doxorubicin in a free and liposomal formulation. <i>International Journal of Pharmaceutics</i> , 2016, 510, 42-47.	5.2	11
29	Micromeritic properties and instrumental analysis of physical mixtures and solid dispersions with adsorbent containing losartan: Comparison of dissolution-differentiating factors. <i>Powder Technology</i> , 2015, 272, 269-275.	4.2	10
30	Multivariate Statistical Optimization of Tablet Formulations Incorporating High Doses of a Dry Herbal Extract. <i>Pharmaceutics</i> , 2019, 11, 79.	4.5	7
31	Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice. <i>PLoS ONE</i> , 2016, 11, e0150791.	2.5	5
32	Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1886-1895.	3.3	5
33	A methodological approach for the biomechanical cause analysis of golf-related lumbar spine injuries. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2014, 17, 1801-1808.	1.6	3
34	Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2959-2972.	4.3	3
35	Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats. <i>Xenobiotica</i> , 2014, 44, 77-88.	1.1	1
36	Pharmacokinetic changes of drugs in a rat model of liver cirrhosis induced by dimethylnitrosamine, alone and in combination with diabetes mellitus induced by streptozotocin. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 1-14.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Exacerbation of tumor necrosis factor-induced vascular leak syndrome by aging. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 133-137.	5.6	0